Physician profile
Richard N Wolf
NPI 1891713079
$378.67
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $170.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.36 | 2019 | |
| Abbott Laboratories | $28.10 | 2019 | |
| Therapeuticsmd, INC. | $24.86 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $21.66 | 2019 | |
| Novo Nordisk INC | $17.70 | 2019 | |
| Abbvie INC. | $16.45 | 2019 | |
| Allergan, INC. | $14.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.